NasdaqGS:CLVS

Stock Analysis Report

Executive Summary

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally.

Snowflake

Fundamentals

Slightly overvalued with limited growth.


Similar Companies

Share Price & News

How has Clovis Oncology's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

7.1%

CLVS

1.7%

US Biotechs

0.5%

US Market


1 Year Return

-84.2%

CLVS

-7.2%

US Biotechs

6.8%

US Market

Return vs Industry: CLVS underperformed the US Biotechs industry which returned -7.2% over the past year.

Return vs Market: CLVS underperformed the US Market which returned 6.8% over the past year.


Shareholder returns

CLVSIndustryMarket
7 Day7.1%1.7%0.5%
30 Day-29.5%-3.4%-0.8%
90 Day-70.2%-1.3%-0.9%
1 Year-84.2%-84.2%-6.3%-7.2%9.2%6.8%
3 Year-89.7%-89.7%14.8%10.9%45.6%36.2%
5 Year-94.0%-94.0%-2.3%-7.0%63.2%45.4%

Price Volatility Vs. Market

How volatile is Clovis Oncology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Clovis Oncology undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CLVS ($3.34) is trading below our estimate of fair value ($10.96)

Significantly Below Fair Value: CLVS is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CLVS is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CLVS is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CLVS's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CLVS has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.


Next Steps

Future Growth

How is Clovis Oncology forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

40.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLVS is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CLVS is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CLVS is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CLVS's revenue (36.7% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: CLVS's revenue (36.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CLVS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Clovis Oncology performed over the past 5 years?

-13.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CLVS is unprofitable, and losses have increased over the past 5 years at a rate of -13.4% per year.

Accelerating Growth: Unable to compare CLVS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CLVS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: CLVS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: CLVS is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: CLVS is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Clovis Oncology's financial position?


Financial Position Analysis

Short Term Liabilities: CLVS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: CLVS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: CLVS has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: CLVS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: CLVS has a low level of unsold assets or inventory.

Debt Coverage by Assets: CLVS has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CLVS has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CLVS has less than a year of cash runway if free cash flow continues to reduce at historical rates of -17.2% each year


Next Steps

Dividend

What is Clovis Oncology's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.0%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate CLVS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CLVS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CLVS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CLVS's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CLVS's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Clovis Oncology's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average management tenure


CEO

Patrick Mahaffy (56yo)

10.5yrs

Tenure

US$6,267,458

Compensation

Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. on April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Offic ...


CEO Compensation Analysis

Compensation vs. Market: Patrick's total compensation ($USD6.27M) is about average for companies of similar size in the US market ($USD1.16M).

Compensation vs Earnings: Patrick's compensation has been consistent with company performance over the past year.


Management Age and Tenure

3.8yrs

Average Tenure

55yo

Average Age

Experienced Management: CLVS's management team is considered experienced (3.8 years average tenure).


Board Age and Tenure

10.5yrs

Average Tenure

63yo

Average Age

Experienced Board: CLVS's board of directors are seasoned and experienced ( 10.5 years average tenure).


Insider Trading

Insider Buying: CLVS insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$233,40021 Aug 19
James Blair
EntityIndividual
Role
Member of the Board of Directors
Director
Shares40,000
Max PriceUS$5.97
BuyUS$279,57619 Aug 19
Patrick Mahaffy
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares50,000
Max PriceUS$5.61
BuyUS$48,76216 Aug 19
Thorlef Spickschen
EntityIndividual
Role
Member of the Board of Directors
Director
Shares8,600
Max PriceUS$5.67
BuyUS$50,23215 Aug 19
Thorlef Spickschen
EntityIndividual
Role
Member of the Board of Directors
Director
Shares9,200
Max PriceUS$5.46
SellUS$473,98618 Mar 19
Domain Associates, L.L.C.
EntityCompany
Shares17,056
Max PriceUS$27.79
BuyUS$54,06708 Mar 19
Armistice Capital LLC
EntityCompany
Shares1,920
Max PriceUS$28.16
SellUS$1,647,66008 Mar 19
Armistice Capital LLC
EntityCompany
Shares2,240,920
Max PriceUS$31.92

Ownership Breakdown


Management Team

  • Dan Muehl (55yo)

    Executive VP & CFO

    • Tenure: 3.6yrs
    • Compensation: US$1.51m
  • Patrick Mahaffy (56yo)

    Co-Founder

    • Tenure: 10.5yrs
    • Compensation: US$6.27m
  • Gillian Ivers-Read (65yo)

    Co-Founder

    • Tenure: 10.5yrs
    • Compensation: US$1.76m
  • Anna Sussman

    Vice President of Investor Relations

    • Tenure: 0yrs
  • Paul Gross (54yo)

    Chief Compliance Officer

    • Tenure: 3.8yrs
  • Ann Bozeman

    Executive Vice President of Human Resources

    • Tenure: 3.1yrs
  • Breanna Burkart

    Vice President of Investor Relations & Corporate Communications

    • Tenure: 3.1yrs
  • Lindsey Rolfe (51yo)

    Executive VP of Clinical

    • Tenure: 4.2yrs
    • Compensation: US$1.82m

Board Members

  • Paul Klingenstein (63yo)

    Director

    • Tenure: 10.5yrs
    • Compensation: US$359.98k
  • Brian Atwood (66yo)

    Director

    • Tenure: 10.8yrs
    • Compensation: US$364.98k
  • Ed McKinley (67yo)

    Director

    • Tenure: 10.8yrs
    • Compensation: US$369.98k
  • Jim Blair (79yo)

    Director

    • Tenure: 10.8yrs
    • Compensation: US$369.98k
  • Ginger Graham (63yo)

    Chairman

    • Tenure: 0.3yrs
    • Compensation: US$357.48k
  • Patrick Mahaffy (56yo)

    Co-Founder

    • Tenure: 10.5yrs
    • Compensation: US$6.27m
  • Thorlef Spickschen (78yo)

    Director

    • Tenure: 10.8yrs
    • Compensation: US$357.48k
  • Keith Flaherty (48yo)

    Director

    • Tenure: 6.8yrs
    • Compensation: US$354.98k
  • Rick Fair (50yo)

    Director

    • Tenure: 1yrs
    • Compensation: US$539.35k
  • Bob Azelby (51yo)

    Director

    • Tenure: 1yrs
    • Compensation: US$538.72k

Company Information

Clovis Oncology, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Clovis Oncology, Inc.
  • Ticker: CLVS
  • Exchange: NasdaqGS
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$182.553m
  • Shares outstanding: 54.66m
  • Website: https://www.clovisoncology.com

Number of Employees


Location

  • Clovis Oncology, Inc.
  • 5500 Flatiron Parkway
  • Suite 100
  • Boulder
  • Colorado
  • 80301
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CLVSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 2011
C6ODB (Deutsche Boerse AG)YesCommon StockDEEURNov 2011

Biography

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offer ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 00:19
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.